Metabolism and pharmacokinetics of radium-223 in prostate cancer.

about

Radium-223 and concomitant therapies: prospects and prudence.Factors affecting (223)Ra therapy: clinical experience after 532 cycles from a single institution.

P2860

Q42343422-1D98F73E-065C-41BB-B2C4-6CE458E9F65E Q53328506-DC0BDCB1-EF75-4E3B-B090-2CB07BC62389

P2860

Metabolism and pharmacokinetics of radium-223 in prostate cancer.

Item

http://www.wikidata.org/entity/Q38367715

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Metabolism and pharmacokinetics of radium-223 in prostate cancer.

@en

type

Item

label

Metabolism and pharmacokinetics of radium-223 in prostate cancer.

@en

prefLabel

Metabolism and pharmacokinetics of radium-223 in prostate cancer.

@en

P1476

Metabolism and pharmacokinetics of radium-223 in prostate cancer.

@en

P2093

Oladapo Yeku

http://www.w3.org/2001/XMLSchema#string

Susan F Slovin

http://www.w3.org/2001/XMLSchema#string

P2860

Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.

Radioisotopes for the palliation of metastatic bone cancer: a systematic review

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

Alpha emitter radium-223 and survival in metastatic prostate cancer

Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation

Molecular mechanisms and treatment of bone metastasis.

Initial treatment patterns and outcome of contemporary prostate cancer patients with bone metastases at initial presentation: data from CaPSURE.

Samarium-153-labelled EDTMP for bone metastases from cancer of the prostate.

Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer.

P304

843-849

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/17425255.2015.1021332

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-03-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25740232

http://www.w3.org/2001/XMLSchema#string

Metabolism and pharmacokinetics of radium-223 in prostate cancer.

about

P2860

P2860

Metabolism and pharmacokinetics of radium-223 in prostate cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698